Denmark · Delayed Price · Currency is DKK Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of DKK 135.04 billion. The enterprise value is 159.67 billion.
| Market Cap | 135.04B |
| Enterprise Value | 159.67B |
Important Dates
The next confirmed earnings date is Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 59.75 million shares outstanding. The number of shares has decreased by -1.73% in one year.
| Current Share Class | 59.75M |
| Shares Outstanding | 59.75M |
| Shares Change (YoY) | -1.73% |
| Shares Change (QoQ) | -3.36% |
| Owned by Insiders (%) | 1.21% |
| Owned by Institutions (%) | 63.39% |
| Float | 59.01M |
Valuation Ratios
The trailing PE ratio is 27.30 and the forward PE ratio is 23.62. Genmab's PEG ratio is 1.14.
| PE Ratio | 27.30 |
| Forward PE | 23.62 |
| PS Ratio | 5.00 |
| PB Ratio | 3.46 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 23.75 |
| P/OCF Ratio | 23.16 |
| PEG Ratio | 1.14 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.50, with an EV/FCF ratio of 28.08.
| EV / Earnings | 30.96 |
| EV / Sales | 5.91 |
| EV / EBITDA | 17.50 |
| EV / EBIT | 18.29 |
| EV / FCF | 28.08 |
Financial Position
The company has a current ratio of 2.46, with a Debt / Equity ratio of 0.89.
| Current Ratio | 2.46 |
| Quick Ratio | 2.44 |
| Debt / Equity | 0.89 |
| Debt / EBITDA | 3.78 |
| Debt / FCF | 6.07 |
| Interest Coverage | 4.96 |
Financial Efficiency
Return on equity (ROE) is 14.00% and return on invested capital (ROIC) is 12.07%.
| Return on Equity (ROE) | 14.00% |
| Return on Assets (ROA) | 8.79% |
| Return on Invested Capital (ROIC) | 12.07% |
| Return on Capital Employed (ROCE) | 11.73% |
| Weighted Average Cost of Capital (WACC) | 7.35% |
| Revenue Per Employee | 8.67M |
| Profits Per Employee | 1.65M |
| Employee Count | 3,119 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 18.58 |
Taxes
In the past 12 months, Genmab has paid 772.19 million in taxes.
| Income Tax | 772.19M |
| Effective Tax Rate | 13.02% |
Stock Price Statistics
The stock price has increased by +27.76% in the last 52 weeks. The beta is 0.70, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +27.76% |
| 50-Day Moving Average | 2,032.15 |
| 200-Day Moving Average | 1,891.03 |
| Relative Strength Index (RSI) | 67.63 |
| Average Volume (20 Days) | 108,628 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genmab had revenue of DKK 27.03 billion and earned 5.16 billion in profits. Earnings per share was 82.78.
| Revenue | 27.03B |
| Gross Profit | 25.15B |
| Operating Income | 8.73B |
| Pretax Income | 5.93B |
| Net Income | 5.16B |
| EBITDA | 9.01B |
| EBIT | 8.73B |
| Earnings Per Share (EPS) | 82.78 |
Balance Sheet
The company has 9.88 billion in cash and 34.51 billion in debt, with a net cash position of -24.63 billion or -412.11 per share.
| Cash & Cash Equivalents | 9.88B |
| Total Debt | 34.51B |
| Net Cash | -24.63B |
| Net Cash Per Share | -412.11 |
| Equity (Book Value) | 38.98B |
| Book Value Per Share | 652.96 |
| Working Capital | 10.87B |
Cash Flow
In the last 12 months, operating cash flow was 5.83 billion and capital expenditures -143.97 million, giving a free cash flow of 5.69 billion.
| Operating Cash Flow | 5.83B |
| Capital Expenditures | -143.97M |
| Depreciation & Amortization | 279.85M |
| Net Borrowing | 34.88B |
| Free Cash Flow | 5.69B |
| FCF Per Share | 95.17 |
Margins
Gross margin is 93.03%, with operating and profit margins of 32.29% and 19.08%.
| Gross Margin | 93.03% |
| Operating Margin | 32.29% |
| Pretax Margin | 21.93% |
| Profit Margin | 19.08% |
| EBITDA Margin | 33.33% |
| EBIT Margin | 32.29% |
| FCF Margin | 21.15% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.73% |
| Shareholder Yield | 1.73% |
| Earnings Yield | 3.82% |
| FCF Yield | 4.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Genmab is 2,453.79, which is 8.58% higher than the current price. The consensus rating is "Buy".
| Price Target | 2,453.79 |
| Price Target Difference | 8.58% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | 20.14% |
| EPS Growth Forecast (3Y) | 14.64% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genmab has an Altman Z-Score of 2.91 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.91 |
| Piotroski F-Score | 4 |